Close
  Indian J Med Microbiol
 

Figure 3 (a) Pancreatic section from normal control group showed normal size of β-cells of islets of Langerhans shown by arrow (H&E, ×400), (b) pancreatic section from diabetic control group showed small-size, atrophic pancreatic islets of Langerhans, which were shown by arrow (H&E, ×400), (c) pancreatic section from Amaryl (0.1 mg/kg) group showed pancreatic islets of Langerhans, which were shaped regularly and arranged evenly shown by arrow (H&E, ×400), (d) pancreatic section from low-dose (200 mg/kg) treated group showed pancreatic islets of Langerhans, which were shaped regularly and arranged evenly shown by arrow (H&E, ×400), (e) Pancreatic section from high-dose (400 mg/kg) treated group showed pancreatic islets of Langerhans, which were shaped regularly and arranged evenly shown by arrow (H&E, ×400).

Figure 3 (a) Pancreatic section from normal control group showed normal size of β-cells of islets of Langerhans shown by arrow (H&E, ×400), (b) pancreatic section from diabetic control group showed small-size, atrophic pancreatic islets of Langerhans, which were shown by arrow (H&E, ×400), (c) pancreatic section from Amaryl (0.1 mg/kg) group showed pancreatic islets of Langerhans, which were shaped regularly and arranged evenly shown by arrow (H&E, ×400), (d) pancreatic section from low-dose (200 mg/kg) treated group showed pancreatic islets of Langerhans, which were shaped regularly and arranged evenly shown by arrow (H&E, ×400), (e) Pancreatic section from high-dose (400 mg/kg) treated group showed pancreatic islets of Langerhans, which were shaped regularly and arranged evenly shown by arrow (H&E, ×400).